Prof Patricia Campbell
@drpmcampbell.bsky.social
Clinical Lead for Heart Failure, Northern Ireland.
Medical Director R&D, Southern Trust NI.
Associate Editor Journal Cardiac Failure
Medical Director R&D, Southern Trust NI.
Associate Editor Journal Cardiac Failure
Reposted by Prof Patricia Campbell
Can what’s on your plate help treat heart failure? 🍽️
@robmentz.bsky.social dives into what a decade of research says about medically tailored meals, and why they might be part of the future of HF care. 🫀
For more details on the study: bit.ly/4lk70EW
@robmentz.bsky.social dives into what a decade of research says about medically tailored meals, and why they might be part of the future of HF care. 🫀
For more details on the study: bit.ly/4lk70EW
August 5, 2025 at 7:48 PM
Can what’s on your plate help treat heart failure? 🍽️
@robmentz.bsky.social dives into what a decade of research says about medically tailored meals, and why they might be part of the future of HF care. 🫀
For more details on the study: bit.ly/4lk70EW
@robmentz.bsky.social dives into what a decade of research says about medically tailored meals, and why they might be part of the future of HF care. 🫀
For more details on the study: bit.ly/4lk70EW
Reposted by Prof Patricia Campbell
AI tools used by English councils downplay women’s health issues, study finds
AI tools used by English councils downplay women’s health issues, study finds
Exclusive: LSE research finds risk of gender bias in care decisions made based on AI summaries of case notes
Artificial intelligence tools used by more than half of England’s councils are downplaying women’s physical and mental health issues and risk creating gender bias in care decisions, research has found.
The study found that when using Google’s AI tool “Gemma” to generate and summarise the same case notes, language such as “disabled”, “unable” and “complex” appeared significantly more often in descriptions of men than women. Continue reading...
www.theguardian.com
August 11, 2025 at 5:16 AM
AI tools used by English councils downplay women’s health issues, study finds
Always the best bit of the conference - debate with the hilarious but profoundly clever Will Watson insisting interventionalists stay away from HF! #BSHMDT2025
May 1, 2025 at 3:43 PM
Always the best bit of the conference - debate with the hilarious but profoundly clever Will Watson insisting interventionalists stay away from HF! #BSHMDT2025
HFpEF session kicked off here at the first BSH MDT meeting in beautiful Cardiff, with a practical work up lecture by the amazing Becky Hyland #25in25
May 1, 2025 at 9:11 AM
HFpEF session kicked off here at the first BSH MDT meeting in beautiful Cardiff, with a practical work up lecture by the amazing Becky Hyland #25in25
Phenomenal multimodality imaging session here at Advanced Imaging 2025 @bsecho.bsky.social @roysocmed.bsky.social @rositazakeri.bsky.social taught me so more MRI tips today than I have ever known 🥰
April 24, 2025 at 1:50 PM
Phenomenal multimodality imaging session here at Advanced Imaging 2025 @bsecho.bsky.social @roysocmed.bsky.social @rositazakeri.bsky.social taught me so more MRI tips today than I have ever known 🥰
Proportionality of MR matters for outcome of Functional MR intervention trials! Brilliant insights from Liam Ring @bsecho.bsky.social @roysocmed.bsky.social
April 24, 2025 at 9:22 AM
Proportionality of MR matters for outcome of Functional MR intervention trials! Brilliant insights from Liam Ring @bsecho.bsky.social @roysocmed.bsky.social
Off to a flying start here at Advanced Imaging 2025 here @roysocmed.bsky.social with @bsecho.bsky.social
Loving this theory of maldistribution of workload predicting response to CRT
Loving this theory of maldistribution of workload predicting response to CRT
April 24, 2025 at 8:54 AM
Off to a flying start here at Advanced Imaging 2025 here @roysocmed.bsky.social with @bsecho.bsky.social
Loving this theory of maldistribution of workload predicting response to CRT
Loving this theory of maldistribution of workload predicting response to CRT
Reposted by Prof Patricia Campbell
"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial."
Présenté ce jour à #ACC25 et publié dans @thelancet.bsky.social.
#MedSky #CardioSky
www.thelancet.com/journals/lan...
Présenté ce jour à #ACC25 et publié dans @thelancet.bsky.social.
#MedSky #CardioSky
www.thelancet.com/journals/lan...
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
Semaglutide increased walking distance in patients with symptomatic peripheral artery
disease and type 2 diabetes. Research implications include the need for future studies
to further elucidate mechan...
www.thelancet.com
March 29, 2025 at 4:41 PM
"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial."
Présenté ce jour à #ACC25 et publié dans @thelancet.bsky.social.
#MedSky #CardioSky
www.thelancet.com/journals/lan...
Présenté ce jour à #ACC25 et publié dans @thelancet.bsky.social.
#MedSky #CardioSky
www.thelancet.com/journals/lan...
Reposted by Prof Patricia Campbell
Are we at an AI tipping point? What are the the challenges? Interesting session on AI #acc25 #AI @accintouch.bsky.social
March 29, 2025 at 5:09 PM
Are we at an AI tipping point? What are the the challenges? Interesting session on AI #acc25 #AI @accintouch.bsky.social
Reposted by Prof Patricia Campbell
From JAMA Cardiology: Finerenone was effective in heart failure patients with mildly reduced or preserved ejection fraction, regardless of atrial fibrillation (AF) status, and new-onset AF was linked to higher risk of adverse outcomes.
#ACC25 https://ja.ma/4iKwgDk
#ACC25 https://ja.ma/4iKwgDk
March 29, 2025 at 5:20 PM
From JAMA Cardiology: Finerenone was effective in heart failure patients with mildly reduced or preserved ejection fraction, regardless of atrial fibrillation (AF) status, and new-onset AF was linked to higher risk of adverse outcomes.
#ACC25 https://ja.ma/4iKwgDk
#ACC25 https://ja.ma/4iKwgDk
Reposted by Prof Patricia Campbell
March 29, 2025 at 4:30 PM
Reposted by Prof Patricia Campbell
March 29, 2025 at 5:27 PM
Reposted by Prof Patricia Campbell
Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky
March 29, 2025 at 3:13 PM
Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky
Reposted by Prof Patricia Campbell
The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM.
Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky
Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky
Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky
March 29, 2025 at 4:02 PM
The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM.
Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky
Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky
Reposted by Prof Patricia Campbell
Intensive medical therapy did not significantly impact the rate of serious CV events at five years in women w/ suspected INOCA, according to findings from WARRIOR presented during a #LBCT session at #ACC25.
Learn more: bit.ly/44a7uYO #MedSky #CardioSky
Learn more: bit.ly/44a7uYO #MedSky #CardioSky
March 29, 2025 at 4:05 PM
Intensive medical therapy did not significantly impact the rate of serious CV events at five years in women w/ suspected INOCA, according to findings from WARRIOR presented during a #LBCT session at #ACC25.
Learn more: bit.ly/44a7uYO #MedSky #CardioSky
Learn more: bit.ly/44a7uYO #MedSky #CardioSky
Reposted by Prof Patricia Campbell
Do you practice in #HeartFailure?
Then please do this survey for @noshreza.bsky.social Dr MarkDrazner Dr. Olivia Gilbert et al!
They want to hear about practicing heart failure specialists #HFAwareness #heartmonth #CardioSky
redcap.wakehealth.edu/redcap/surve...
🙏♥️❤️🩹🫀
Then please do this survey for @noshreza.bsky.social Dr MarkDrazner Dr. Olivia Gilbert et al!
They want to hear about practicing heart failure specialists #HFAwareness #heartmonth #CardioSky
redcap.wakehealth.edu/redcap/surve...
🙏♥️❤️🩹🫀
Advanced Heart Failure/Transplant Cardiology Survey
redcap.wakehealth.edu
February 14, 2025 at 8:38 PM
Do you practice in #HeartFailure?
Then please do this survey for @noshreza.bsky.social Dr MarkDrazner Dr. Olivia Gilbert et al!
They want to hear about practicing heart failure specialists #HFAwareness #heartmonth #CardioSky
redcap.wakehealth.edu/redcap/surve...
🙏♥️❤️🩹🫀
Then please do this survey for @noshreza.bsky.social Dr MarkDrazner Dr. Olivia Gilbert et al!
They want to hear about practicing heart failure specialists #HFAwareness #heartmonth #CardioSky
redcap.wakehealth.edu/redcap/surve...
🙏♥️❤️🩹🫀
Reposted by Prof Patricia Campbell
Baroreflex activation therapy modulates baroreceptor nerve activity, & has been shown to improve exercise capacity & QoL in HFrEF.
This JCF brief report presents a real-world analysis showing that BAT reduces hospital visits & LoS.
#THT2025
🔗 bit.ly/4aW92Y2
This JCF brief report presents a real-world analysis showing that BAT reduces hospital visits & LoS.
#THT2025
🔗 bit.ly/4aW92Y2
February 12, 2025 at 8:06 PM
Baroreflex activation therapy modulates baroreceptor nerve activity, & has been shown to improve exercise capacity & QoL in HFrEF.
This JCF brief report presents a real-world analysis showing that BAT reduces hospital visits & LoS.
#THT2025
🔗 bit.ly/4aW92Y2
This JCF brief report presents a real-world analysis showing that BAT reduces hospital visits & LoS.
#THT2025
🔗 bit.ly/4aW92Y2
Food for thought? Maybe because access to these interventions will always be limited where I am, but I am always sceptical. Ready to be proven wrong
🔥 Science Alert!
REBALANCE-HF assessed permanent ablation of the right greater splanchnic nerve in HFpEF. In this sub-study, the authors found that permanent GSN ablation reduced stressed blood volume, thus reducing RAP & PCWP. #THT2025
🔗 bit.ly/4hXV75Q
REBALANCE-HF assessed permanent ablation of the right greater splanchnic nerve in HFpEF. In this sub-study, the authors found that permanent GSN ablation reduced stressed blood volume, thus reducing RAP & PCWP. #THT2025
🔗 bit.ly/4hXV75Q
February 13, 2025 at 5:56 PM
Food for thought? Maybe because access to these interventions will always be limited where I am, but I am always sceptical. Ready to be proven wrong
Reposted by Prof Patricia Campbell
🚨New science alert! HM3 LVADs are associated w/hemodynamic related events like RVF.
In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF.
#THT2025
🔗: bit.ly/3CEDDN7
In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF.
#THT2025
🔗: bit.ly/3CEDDN7
February 13, 2025 at 3:49 PM
🚨New science alert! HM3 LVADs are associated w/hemodynamic related events like RVF.
In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF.
#THT2025
🔗: bit.ly/3CEDDN7
In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF.
#THT2025
🔗: bit.ly/3CEDDN7
Reposted by Prof Patricia Campbell
🫀 A new study validates the SPICT (Supportive and Palliative Care Indicator Tool), which identifies hospitalized HF pts at high mortality risk.
Key Findings:
✔ SPICT-JP +: >3x ⬆️ mort risk
✔ Aids in advance-care planning for EoL decisions.
🔗https://bit.ly/4g0Lou8
Key Findings:
✔ SPICT-JP +: >3x ⬆️ mort risk
✔ Aids in advance-care planning for EoL decisions.
🔗https://bit.ly/4g0Lou8
February 3, 2025 at 2:51 PM
🫀 A new study validates the SPICT (Supportive and Palliative Care Indicator Tool), which identifies hospitalized HF pts at high mortality risk.
Key Findings:
✔ SPICT-JP +: >3x ⬆️ mort risk
✔ Aids in advance-care planning for EoL decisions.
🔗https://bit.ly/4g0Lou8
Key Findings:
✔ SPICT-JP +: >3x ⬆️ mort risk
✔ Aids in advance-care planning for EoL decisions.
🔗https://bit.ly/4g0Lou8
Reposted by Prof Patricia Campbell
Current guidelines for primary prev ICD might not apply to contemporary pts given advances in HF Rx. Or do they?
🌟 This joint publication in #JCF & @hrs_journal summarizes data to date and proposes clinical trial to reassess.
🔗 bit.ly/3CEUj7a
🌟 This joint publication in #JCF & @hrs_journal summarizes data to date and proposes clinical trial to reassess.
🔗 bit.ly/3CEUj7a
February 5, 2025 at 2:26 PM
Current guidelines for primary prev ICD might not apply to contemporary pts given advances in HF Rx. Or do they?
🌟 This joint publication in #JCF & @hrs_journal summarizes data to date and proposes clinical trial to reassess.
🔗 bit.ly/3CEUj7a
🌟 This joint publication in #JCF & @hrs_journal summarizes data to date and proposes clinical trial to reassess.
🔗 bit.ly/3CEUj7a
Reposted by Prof Patricia Campbell
This 🔥 new brief report describes a first-in-human feasibility study to evaluate the safety/efficacy of the Reprieve System, a bedside fluid mgmnt device that can
1) measure UO
2) semi-auto titrate IV diuretics
3) titrate saline replacement
#THT2025
🔗 bit.ly/4huGrvq
1) measure UO
2) semi-auto titrate IV diuretics
3) titrate saline replacement
#THT2025
🔗 bit.ly/4huGrvq
February 11, 2025 at 3:24 PM
This 🔥 new brief report describes a first-in-human feasibility study to evaluate the safety/efficacy of the Reprieve System, a bedside fluid mgmnt device that can
1) measure UO
2) semi-auto titrate IV diuretics
3) titrate saline replacement
#THT2025
🔗 bit.ly/4huGrvq
1) measure UO
2) semi-auto titrate IV diuretics
3) titrate saline replacement
#THT2025
🔗 bit.ly/4huGrvq
Reposted by Prof Patricia Campbell
Acute HF differs from chronic HF, especially in HFmrEF/HFpEF, due to marked neurohormonal activation, which serves as a therapeutic target.
In this 🔥 Perspectives piece, the authors describe the role of rapid uptitration of neurohormonal blockade in these pts👇
🔗 bit.ly/4gF4ned
In this 🔥 Perspectives piece, the authors describe the role of rapid uptitration of neurohormonal blockade in these pts👇
🔗 bit.ly/4gF4ned
February 11, 2025 at 7:19 PM
Acute HF differs from chronic HF, especially in HFmrEF/HFpEF, due to marked neurohormonal activation, which serves as a therapeutic target.
In this 🔥 Perspectives piece, the authors describe the role of rapid uptitration of neurohormonal blockade in these pts👇
🔗 bit.ly/4gF4ned
In this 🔥 Perspectives piece, the authors describe the role of rapid uptitration of neurohormonal blockade in these pts👇
🔗 bit.ly/4gF4ned
Reposted by Prof Patricia Campbell
Is TTR biology the sole driver of disease progression? In an era of multiple therapies for ATTR-CM, is choosing one disease-modifying agent over another as important as early disease recognition & treatment?
Dr. Mathew Maurer tackles this question!
bit.ly/42MGNZN
Dr. Mathew Maurer tackles this question!
bit.ly/42MGNZN
February 11, 2025 at 8:28 PM
Is TTR biology the sole driver of disease progression? In an era of multiple therapies for ATTR-CM, is choosing one disease-modifying agent over another as important as early disease recognition & treatment?
Dr. Mathew Maurer tackles this question!
bit.ly/42MGNZN
Dr. Mathew Maurer tackles this question!
bit.ly/42MGNZN